ADIL
NASDAQ
US
Adial Pharmaceuticals, Inc - Common Stock
$1.69
▼ $-0.04
(-2.31%)
Vol 43K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$5.9M
ROE
-197.7%
D/E
0.00
Beta
1.36
52W
$0–$1
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Earnings
Beat rate: 80.0%
Next Report
May 12, 2026
EPS Estimate: $-2.30
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-2.30 | — | — |
| Dec 2025 | $-2.19 | $-3.07 | $-0.88 |
| Sep 2025 | $-3.57 | $-2.00 | +$1.57 |
| Jun 2025 | $-6.38 | $-4.50 | +$1.88 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$2.1M | -$2.2M | -$2.0M | -$1.8M | -$2.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -191.3% | -191.3% | -191.3% | -191.3% | -191.3% | -197.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 4.34 |
Key Ratios
ROA (TTM)
-153.7%
P/B
1.6
EPS (TTM)
$-0.93
CF/Share
$-4.58
52W High
$1.13
52W Low
$0.22
$0.22
52-Week Range
$1.13
Financial Health
Free Cash Flow
-$1.3M
Cash
$5.9M
As of Dec 31, 2025
How does ADIL compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ADIL valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
1.6
▼
24%
below
peers
(2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ADIL profitability vs Pharmaceuticals peers
ROE
-197.7%
▼
264%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-153.7%
▼
310%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
ADIL financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
4.3
▲
29%
above
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
1.4
▲
45%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
ADIL fundamentals radar
ADIL
Peer median
Industry
ADIL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ADIL vs peers: key metrics
Top Holders
Top 5: 9.0%Armistice Capital, LLC
7.16%
$168K
Citadel Advisors Llc
0.62%
$14K
Vanguard Group Inc
0.44%
$10K
Geode Capital Management, L…
0.44%
$10K
Jane Street Group, LLC
0.34%
$8K
As of Dec 31, 2025
Latest News
No related news yet